Pattern of Frequent But Nontargeted Pharmacologic Thromboprophylaxis for Hospitalized Patients With Cancer at Academic Medical Centers Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, September 17, 2015

Pattern of Frequent But Nontargeted Pharmacologic Thromboprophylaxis for Hospitalized Patients With Cancer at Academic Medical Centers



open access

 Pattern of Frequent But Nontargeted Pharmacologic Thromboprophylaxis for Hospitalized Patients With Cancer at Academic Medical Centers: A Prospective, Cross-Sectional, Multicenter Study

 Conclusion We conclude that pharmacologic thromboprophylaxis is frequently administered to hospitalized patients with cancer but that nearly one third of patients are considered to have relative contraindications for prophylactic anticoagulation. Pharmacologic thromboprophylaxis in hospitalized patients with cancer is commonly prescribed without regard to the presence or absence of concomitant risk factors for VTE.

 See accompanying editorial on page 1754
 Evidence-Based Medicine for Thromboprophylaxis in Hospitalized Patients With Cancer: Why Aren't We There Yet?

 ....Considering that 60% of venous thromboembolism cases are related to hospitalization,16 that 20% of venous thromboembolism occur in oncology patients,17 and that venous thromboembolism is associated with increased in-hospital mortality,18 it is disheartening that good quality research has not been done to address in-hospital thromboprophylaxis in patients with cancer. The lack of evidence to guide best practice in this everyday clinical setting is unacceptable. Zwicker et al4 have sounded an alarm. The oncology community needs to take action.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.